title: The effects of octreotide on basal and stimulated hormone levels in patients with carcinoid syndrome.
abstract: The carcinoid syndrome, a common feature of small intestinal carcinoid tumors with liver metastases, includes flushing, diarrhea, bronchoconstriction, and right heart failure. The etiology of the carcinoid syndrome is not well understood, but serotonin seems to be involved in the diarrhea, whereas tachykinins may play a role in the flush reaction. In a double blind placebo-controlled study, we studied the effect of octreotide in 20 patients with midgut carcinoid tumors and liver metastases. A sc injection of 50 micrograms octreotide caused a significant (P less than 0.001) decrease in median plasma tachykinins and serum pancreatic polypeptide, GH, and insulin for up to 4 h. Administration of octreotide (50 micrograms, twice daily, sc) caused a 26% decrease in urinary 5-hydroxyindoleacetia acid excretion, but the number of flushing attacks or bowel movements did not change significantly. A typical flush was provoked by pentagastrin, and plasma tachykinin and serotonin levels were measured. The flush reaction was graded on a 10-point visual analog scale. Octreotide (50 micrograms, sc) given 45 min before flush stimulation prevented tachykinin release completely and significantly reduced the median flushing score from 8.5 to 2. Placebo administered in the same way did not prevent tachykinin release after pentagastrin administration. Thus, octreotide prevents pentagastrin-induced flushing and the related hormonal changes in patients with the carcinoid syndrome.
authors: Ludwig Institute for Cancer Research, University Hospital, Uppsala, Sweden.
authors: K
authors: K
authors: Oberg
authors: I
authors: I
authors: Norheim
authors: E
authors: E
authors: Theodorsson
authors: H
authors: H
authors: Ahlman
authors: G
authors: G
authors: Lundqvist
authors: L
authors: L
authors: Wide
mesh_terms: D000368:Aged; D004311:Double-Blind Method; D005260:Female; D005483:Flushing / Q000517:prevention & control*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000652:urine; D007328:Insulin / Q000097:blood; D007414:Intestinal Neoplasms / Q000097:blood* / Q000188:drug therapy; D008113:Liver Neoplasms / Q000556:secondary; D008297:Male; D008303:Malignant Carcinoid Syndrome / Q000097:blood* / Q000188:drug therapy; D008875:Middle Aged; D015282:Octreotide / Q000493:pharmacokinetics / Q000627:therapeutic use*; D010191:Pancreatic Polypeptide / Q000097:blood; D010418:Pentagastrin; D015320:Tachykinins / Q000097:blood
chemical_list: D007328:Insulin; D015320:Tachykinins; D006897:Hydroxyindoleacetic Acid; D010191:Pancreatic Polypeptide; D010418:Pentagastrin; D015282:Octreotide